ReviewDrugs2016

Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations.

Paul C Barnfield et al.PubMed ↗Publisher ↗

No numbers read from the abstract.